Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence and Food Effect of CC-486 in Advanced Cancer
NCT02223052Phase 1Completed
- Sponsor
- Celgene Corporation
- Start
- Oct 2014
- Primary completion
- Jun 2018
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of CC-486 in myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), multiple myeloma (MM) and 3 more (4 arms), sponsored by Celgene Corporation. Primary endpoints: Maximum Plasma Concentration at Day 2, Time to Maximum Plasma Concentration at Day 2 and 5 more. Started Oct 2014; status: completed.
02
Drugs
CC-486
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)multiple myeloma (MM)non-Hodgkin lymphoma (NHL)Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT02223052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02223052.